Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
Epstein-Barr virus (EBV)-associated lymphoproliferative disease (LPD) is a life-threatening complication following hematopoietic stem cell transplantation (HSCT). Therefore, early diagnosis of EBV reactivation and pre-emptive therapy may be clinically useful. We report three patients who presented with an extremely high EBV load in peripheral blood mononuclear cells and plasma without evidence of EBV disease. Following pre-emptive therapy with a single dose of rituximab, a concordant decrease of EBV-genome copies and B lymphocytes was observed. In all three patients, no EBV-associated LPD occurred. We conclude that pre-emptive therapy with rituximab appears to be effective for prevention of EBV-associated LPD after HSCT.
Gruhn
B
B
Department of Pediatrics, University of Jena, Jena, Germany.
Meerbach
A
A
Häfer
R
R
Zell
R
R
Wutzler
P
P
Zintl
F
F
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017809:Fatal Outcome; D005260:Female; D016679:Genome, Viral; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D008232:Lymphoproliferative Disorders / Q000517:prevention & control* / Q000821:virology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D000069283:Rituximab; D016896:Treatment Outcome; D019562:Viral Load; D014775:Virus Activation / Q000187:drug effects
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D000069283:Rituximab